Jane Starczynski
Overview
Explore the profile of Jane Starczynski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maybury B, James L, Phillips N, Venkatadasari I, Qureshi I, Riley J, et al.
Blood
. 2024 Apr;
144(1):113-117.
PMID: 38648564
A reciprocal t(3;8) BCL6::MYC fusion is common in large B-cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double-hit cases are not adverse, whereas t(3;8)-MYC/BCL6 lymphoma has an inferior prognosis...
2.
Zaakouk M, Van Bockstal M, Galant C, Callagy G, Provenzano E, Hunt R, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900303
The assessment of PD-L1 expression in TNBC is a prerequisite for selecting patients for immunotherapy. The accurate assessment of PD-L1 is pivotal, but the data suggest poor reproducibility. A total...
3.
Rakha E, Tan P, Quinn C, Provenzano E, Shaaban A, Deb R, et al.
J Clin Pathol
. 2022 Dec;
76(4):217-227.
PMID: 36564170
The last UK breast cancer (BC) human epidermal growth factor receptor 2 (HER2) testing guideline recommendations were published in 2015. Since then, new data and therapeutic strategies have emerged. The...
4.
Katayama A, Starczynski J, Toss M, Shaaban A, Provenzano E, Quinn C, et al.
Histopathology
. 2022 Jul;
81(4):511-519.
PMID: 35879836
Background And Aims: Chromosome 17 alterations affect the assessment of HER2 gene amplification in breast cancer (BC), but its clinical significance remains unclear. This study aimed to identify the prevalence...
5.
Rudzki Z, Starczynski J, Dowds J, Pemberton N
Br J Haematol
. 2021 May;
195(2):154.
PMID: 33991335
No abstract available.
6.
Leung S, Nielsen T, Zabaglo L, Arun I, Badve S, Bane A, et al.
Histopathology
. 2019 Apr;
75(2):225-235.
PMID: 31017314
Aims: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The International...
7.
Leung S, Nielsen T, Zabaglo L, Arun I, Badve S, Bane A, et al.
NPJ Breast Cancer
. 2017 Jul;
2:16014.
PMID: 28721378
Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay for Ki67 immunohistochemistry has been...
8.
Ibrahim M, Parry S, Wilkinson D, Bilbe N, Allen D, Forrest S, et al.
J Thorac Oncol
. 2016 Jul;
11(12):2241-2247.
PMID: 27468935
Introduction: Diagnostic immunohistochemistry (IHC) is increasingly accepted as a screening method for anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements in NSCLC. We have sought to establish an ongoing robust...
9.
Nelson L, McKeen H, Marshall A, Mulrane L, Starczynski J, Storr S, et al.
Oncotarget
. 2015 Apr;
6(14):12209-23.
PMID: 25906750
FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL's prognostic...
10.
Polley M, Leung S, Gao D, Mastropasqua M, Zabaglo L, Bartlett J, et al.
Mod Pathol
. 2015 Feb;
28(6):778-86.
PMID: 25698062
Although an important biomarker in breast cancer, Ki67 lacks scoring standardization, which has limited its clinical use. Our previous study found variability when laboratories used their own scoring methods on...